<SUBMISSION>
<ACCESSION-NUMBER>0000950134-07-007286
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>1
<PERIOD>20070402
<ITEMS>3.01
<ITEMS>8.01
<FILING-DATE>20070402
<DATE-OF-FILING-DATE-CHANGE>20070402
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADEZA BIOMEDICAL CORP
<CIK>0000902482
<ASSIGNED-SIC>3825
<IRS-NUMBER>770054952
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-20703
<FILM-NUMBER>07740238
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>1240 ELKO DR
<CITY>SUNNYVALE
<STATE>CA
<ZIP>94089
</BUSINESS-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f28879e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, DC 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported): April&nbsp;2, 2007</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Cytyc Prenatal Products Corp.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact Name of Registrant as Specified in Its Charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B><BR>
(State or Other Jurisdiction of Incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>0-20703</B><BR>
(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>77-0054952</B><BR>
(IRS Employer Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>1240 Elko Drive, Sunnyvale, CA</B><BR>
(Address of Principal Executive Offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>94089</B><BR>
(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s Telephone Number, Including Area Code: <B>(408)&nbsp;745-0975</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Adeza Biomedical Corporation</B><BR>
(Former Name or Former Address, if Changed Since Last Report)</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction
A.2. below):
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Introduction</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As previously disclosed, on February&nbsp;11, 2007, Adeza Biomedical Corporation, a Delaware
corporation (the &#147;Company&#148;), Cytyc Corporation, a Delaware corporation (&#147;Cytyc&#148;), and Augusta
Medical Corporation, a Delaware corporation and a direct wholly-owned subsidiary of Cytyc
(&#147;Purchaser&#148;), entered into an Agreement and Plan of Merger (the &#147;Merger Agreement&#148;). Pursuant to
the Merger Agreement, Purchaser offered to purchase all of the shares of the Company&#146;s common
stock, par value $0.001 per share (the &#147;Shares&#148;), for a price of $24.00 per Share, net to the
holder thereof, in cash (the &#147;Offer Price&#148;), upon the terms and subject to the conditions set forth
in the Offer to Purchase, dated February&nbsp;16, 2007 (the &#147;Offer to Purchase&#148;), and the related Letter
of Transmittal (which, together with the Offer to Purchase, as amended or supplemented, constitute
the &#147;Offer&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the expiration of the subsequent offering period of the Offer at 12:00 midnight, New York
City time, on Friday, March&nbsp;30, 2007, Purchaser owned or had accepted for payment 16,816,572&nbsp;Shares, representing approximately 96% of the outstanding Shares. On April&nbsp;2, 2007, pursuant to
the terms of the Merger Agreement, Purchaser merged with and into the Company (the &#147;Merger&#148;), with
the Company continuing as the surviving corporation and a wholly-owned subsidiary of Cytyc. In
connection with the Merger, the Company&#146;s name was changed from &#147;Adeza Biomedical Corporation&#148; to
&#147;Cytyc Prenatal Products Corp.&#148;
</DIV>
<!-- link2 "Item&nbsp;3.01. <U>Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.</U>" -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Item&nbsp;3.01. <U>Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of the Merger, the Company no longer fulfills the numerical listing requirements
of The NASDAQ Global Select Market. Accordingly, following completion of the Merger, the Company
notified The NASDAQ Stock Market and requested that the Shares be withdrawn from listing on The
NASDAQ Global Select Market prior to the open of trading on April&nbsp;3, 2007. As a result, the Shares
will no longer be listed on The NASDAQ Global Select Market. The Company also intends to file with
the Securities and Exchange Commission (the &#147;SEC&#148;) a Certification on Form&nbsp;15 under the Securities
Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), requesting that the Common Stock be
deregistered and that the Company&#146;s reporting obligations under Sections&nbsp;13 and 15(d) of the
Exchange Act be suspended.
</DIV>
<!-- link2 "Item&nbsp;8.01. <U>Other Events.</U>" -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Item&nbsp;8.01. <U>Other Events.</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Closing of the Merger</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On April&nbsp;2, 2007, pursuant to the terms of the Merger Agreement, Purchaser merged with and
into the Company, with the Company continuing as the surviving corporation and a wholly-owned
subsidiary of Cytyc. In connection with the Merger, the Company&#146;s name was changed from &#147;Adeza
Biomedical Corporation&#148; to &#147;Cytyc Prenatal Products Corp.&#148;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "SIGNATURES" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CYTYC PRENATAL PRODUCTS CORP.<BR>
(f/k/a ADEZA BIOMEDICAL CORPORATION)<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Patrick J. Sullivan&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Patrick J. Sullivan&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Date: April 2, 2007
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
